Allogeneic hematopoietic stem cell transplantation for acute leukemia, chronic leukemia, and myelodysplasia

More than 20,000 patients have survived 5 or more years after allogeneic tr ansplantation, and the number of allogeneic transplantations performed each year continues to increase rapidly. The indications for allogeneic bone ma rrow transplantation are beginning to change as research continues on the u se of transplantation to treat genetic diseases. This article focuses on th e use of allogeneic bone marrow transplantation for the treatment of hemato logic malignancies, including acute myelogenous leukemia, chronic myelogeno us leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, and ch ronic lymphocytic leukemia.